4D Molecular Therapeutics, Inc. (FDMT)

25,34 -0,30 (-1,17%) Börsenschluss: 04:00PM EDT

4D Molecular Therapeutics, Inc.

5858 Horton Street
Suite 455
Emeryville, CA 94608
United States
510 505 2680
https://www.4dmoleculartherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 171

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. John F. Milligan Ph.D.	Executive Chairman	150k	N/A	1961
Dr. David H. Kirn M.D.	Co-Founder, CEO & Director	1,01M	N/A	1963
Dr. Fariborz Kamal Ph.D.	President & COO	786,2k	N/A	1963
Dr. Noriyuki Kasahara M.D., Ph.D.	Chief Scientific Officer	201,29k	N/A	1963
Dr. Robert Y. Kim M.B.A., M.D.	Chief Medical Officer	704,84k	N/A	1961
Ms. Theresa Janke	Co-Founder & Chief of Staff	652,32k	N/A	1975
Mr. Uneek Mehra	Chief Financial & Business Officer	N/A	N/A	1972
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1973
Dr. An Song Ph.D.	Chief Development Officer	N/A	N/A	N/A
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.	Senior VP & Therapeutic Area Head of Pulmonology	N/A	N/A	1961

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Corporate Governance

4D Molecular Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 2, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.